reading non-peptide threads from 2024 and half of it aged badly
reading non-peptide threads from 2024 and half of it aged badly. Making the case below, and I expect to lose some of it in the comments.
The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.
Assumed the peptide purity conversations transferred and they do not. Different analytical problem entirely.
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.
phase 3 is where the comparison becomes fair
Which programme and which readout are you quoting?
daily dosing, not weekly, so the exposure profile is different
Read both programme names carefully after mixing them up in a comment and being politely corrected.
[deleted]
I would not assume the tolerability profile transfers exactly. Similar class effects, different exposure profile.
a non-peptide agonist does not degrade the way a peptide does
a non-peptide agonist does not degrade the way a peptide does
Adding the standing caveat — unapproved, and research material is not for human use.
Same view. The analytical problem is different enough that the usual purity discussions here do not transfer cleanly.
daily dosing changes adherence in both directions
The analytical point, which this board keeps getting wrong by importing habits from the peptide side.
For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.
So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
Corrected a cross-class dose comparison in the title. The body is untouched.
Daily dosing, so what does the exposure profile look like across the day?
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
identity testing on a small molecule is a different analytical problem
- 1Read both programme names carefully after mixing them up in a comment and…7 comments in this branch · started by u/piotr_bruun
- 2The analytical point, which this board keeps getting wrong by importing…6 comments in this branch · started by u/first_hundred